As of 2024-12-13, the Relative Valuation of Cardiff Oncology Inc (CRDF) is (29.53) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.27 USD, the upside of Cardiff Oncology Inc based on Relative Valuation is -1003.0%.
The range of the Relative Valuation is (27.30) - (25.32) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.0x - 31.3x | 26.2x |
| Forward P/E multiples | 19.0x - 19.4x | 19.2x |
| Fair Price | (27.30) - (25.32) | (29.53) |
| Upside | -934.7% - -874.2% | -1003.0% |
| Date | P/E |
| 2024-11-25 | -1.88 |
| 2024-11-22 | -1.88 |
| 2024-11-21 | -1.92 |
| 2024-11-20 | -1.94 |
| 2024-11-19 | -2.01 |
| 2024-11-18 | -1.98 |
| 2024-11-15 | -1.98 |
| 2024-11-14 | -2.18 |
| 2024-11-13 | -2.28 |
| 2024-11-12 | -2.41 |
| 2024-11-11 | -2.66 |
| 2024-11-08 | -2.37 |
| 2024-11-07 | -3.14 |
| 2024-11-06 | -2.93 |
| 2024-11-05 | -2.83 |
| 2024-11-04 | -2.87 |
| 2024-11-01 | -2.46 |
| 2024-10-31 | -2.40 |
| 2024-10-30 | -2.40 |
| 2024-10-29 | -2.40 |
| 2024-10-28 | -2.30 |
| 2024-10-25 | -2.17 |
| 2024-10-24 | -2.10 |
| 2024-10-23 | -2.20 |
| 2024-10-22 | -2.16 |
| 2024-10-21 | -2.13 |
| 2024-10-18 | -2.23 |
| 2024-10-17 | -2.14 |
| 2024-10-16 | -2.14 |
| 2024-10-15 | -2.05 |
| 2024-10-14 | -2.02 |
| 2024-10-11 | -2.02 |
| 2024-10-10 | -1.94 |
| 2024-10-09 | -1.94 |
| 2024-10-08 | -2.10 |
| 2024-10-07 | -2.05 |
| 2024-10-04 | -2.00 |
| 2024-10-03 | -1.94 |
| 2024-10-02 | -1.98 |
| 2024-10-01 | -1.90 |
| 2024-09-30 | -2.05 |
| 2024-09-27 | -2.13 |
| 2024-09-26 | -2.12 |
| 2024-09-25 | -2.06 |
| 2024-09-24 | -2.01 |
| 2024-09-23 | -1.98 |
| 2024-09-20 | -2.06 |
| 2024-09-19 | -1.94 |
| 2024-09-18 | -1.89 |
| 2024-09-17 | -1.95 |